Croda in the news

Croda's half-year results show a focus on reinventing existing technologies, leading to renewed demand for a veteran beauty ingredient and a slow recovery from customer destocking across its diversified business segments.

Croda International PLC shares fell Friday, underperforming the broader market.

Croda's stock shows strong year-to-date gains in 2026 supported by positive analyst ratings and a strategic focus on specialty ingredients.

Croda International's shares fell 2.86% to 33.60 on Tuesday, underperforming the broader market.

Croda Beauty won a sustainability award for its innovative technology that drastically reduces biodegradability testing time for cosmetic ingredients.

Croda International reported increased half-year sales and pre-tax profit, driven by strong growth in Consumer Care and successful transformation efforts.

Croda's shares increased after the speciality chemicals group reported faster second-quarter growth, driven by strong Consumer Care performance, and maintained its full-year outlook.

Croda International reported a 5% increase in first-half sales to 881 million, with adjusted operating profit rising 7% to 156 million, maintaining its 2026 outlook due to strong Q2 growth.

Croda International reported half-year results in line with expectations, driven by strong consumer care sales, while other segments showed mixed performance.

Croda International reported 4.6% organic sales growth in the first half, maintaining full-year guidance, with strong performance in consumer care and strategic focus on niche markets.

Croda International saw increased profit and improved margins in the first half of 2026, driven by strong innovation and growth in its Consumer Care segment.

Croda International's stock rose 3.95% to £29.76, significantly outperforming a declining FTSE 100 Index.

Goldman Sachs has upgraded its outlook on London-listed specialty chemicals manufacturer Croda as the firm pivots toward high-margin life sciences and personal care ingredients.

Croda is implementing greener manufacturing platforms like GAP-PS and synthetic biology to produce sustainable, high-performance peptides and hair-identical proteins.

Financial analysts have kept their price targets for Croda International unchanged following a recent review of the company's valuation and market position.

Croda International faces significant earnings pressure and dividend sustainability risks while undergoing leadership changes and strategic expansion into Asian markets.

Croda launched the 'Beauty of Zero' program to drive sustainable ingredient innovation and biotechnology in the beauty manufacturing sector.

Croda Beauty Active launched an encapsulated peptide technology called Matrixyl® Neolide™ to improve bioavailability in longevity-focused skincare products.

Croda maintained its financial outlook after Q1 trading showed slight currency-adjusted growth led by beauty and fragrance innovations.

Croda reported a 1% rise in Q1 sales and reiterated its 2026 guidance, driven by growth in Consumer Care despite declines in Life Sciences and Industrial segments.